Last reviewed · How we verify
artesunate sachets
Artesunate is an artemisinin derivative that generates reactive oxygen species and alkylates parasite proteins, killing malaria parasites and other blood-stage pathogens.
Artesunate is an artemisinin derivative that generates reactive oxygen species and alkylates parasite proteins, killing malaria parasites and other blood-stage pathogens. Used for Severe malaria (Plasmodium falciparum and other Plasmodium species), Uncomplicated malaria (in combination therapy).
At a glance
| Generic name | artesunate sachets |
|---|---|
| Sponsor | Pfizer |
| Drug class | Artemisinin derivative |
| Target | Plasmodium parasites (multiple targets including heme and parasite proteins) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Artesunate is a semi-synthetic artemisinin compound that acts as a prodrug, converted in vivo to dihydroartemisinin. It generates free radicals and reactive oxygen species that damage parasite membranes and proteins, leading to rapid parasite death. The drug is particularly effective against Plasmodium falciparum and has activity against other Plasmodium species and some other parasites.
Approved indications
- Severe malaria (Plasmodium falciparum and other Plasmodium species)
- Uncomplicated malaria (in combination therapy)
Common side effects
- Anemia
- Elevated liver enzymes
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
Key clinical trials
- Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria (PHASE2)
- Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine (PHASE2, PHASE3)
- Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients (PHASE3)
- A Study Comparing Blood Levels After Single-Dose Administration Of Artesunate Sachets (Pfizer) Versus Single-Dose Administration Of Arsuamoon® Tablets (Guilin-China) In Healthy Subjects (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- artesunate sachets CI brief — competitive landscape report
- artesunate sachets updates RSS · CI watch RSS
- Pfizer portfolio CI